Exploring doxepin brand names and global market dynamics

Published

doxepin brand name
Table of Contents

Doxepin, a tricyclic antidepressant with dual therapeutic applications in psychiatry and dermatology, exemplifies how brand naming conventions and regulatory frameworks shape pharmaceutical markets. From Sinequan’s legacy in geriatric depression to Zonalon’s niche in chronic pruritus, each formulation reflects distinct clinical priorities, patent histories, and formulary inclusions. This analysis dissects the interplay between brand identity, therapeutic innovation, and economic accessibility, revealing how regional approvals, patent expirations, and prescribing trends influence patient outcomes and healthcare systems worldwide.

The evolution of doxepin brands underscores broader pharmaceutical industry dynamics, where generic competition, off-label adoption, and regulatory divergence create fragmented landscapes. While branded products often command premium pricing through patent protections, their clinical differentiation—such as extended-release mechanisms or topical delivery systems—can justify market segmentation. Meanwhile, generics accelerate affordability but may introduce variability in bioavailability, particularly for complex formulations like oral concentrates or dermatological gels. Understanding these nuances is critical for clinicians, formulary committees, and policymakers navigating cost-effectiveness, adherence, and therapeutic efficacy in an era of escalating drug expenditures.

doxepin brand name

Market Presence and Brand Variations of Doxepin Across Global Pharmaceutical Landscapes

Doxepin, a tricyclic antidepressant (TCA) with dual applications in psychiatry and dermatology, exhibits significant variations in brand naming, regulatory approval, and formulary inclusion depending on geographic and therapeutic contexts. These differences reflect regional pharmaceutical policies, historical drug development priorities, and the evolving therapeutic indications for doxepin—ranging from major depressive disorder (MDD) to chronic pruritus and topical anti-inflammatory use. Below, a comparative analysis highlights how generic and branded formulations are positioned in key markets, alongside regulatory and formulary influences that shape their availability.

Country-Specific Trade Names and Regulatory Approval Status

The global distribution of doxepin brands varies markedly due to differences in regulatory pathways, patent expirations, and local manufacturing capabilities. The following table compares generic and branded formulations across five major markets, including their primary indications and formulary status.
Market Brand Name (Generic vs. Branded) Regulatory Approval Status (Year) Primary Therapeutic Claims Key Formulary Inclusions
United States Generic (e.g., Doxepin HCl) FDA (1969, as Sinequan®; generic approval post-patent expiry)
  • Oral: Major depressive disorder (MDD), anxiety disorders, insomnia.
  • Topical: Pruritus (e.g., Zonalon® 5% cream, discontinued in 2019).
  • VA/DoD Formulary (oral doxepin for MDD).
  • WHO Model List of Essential Medicines (oral, 20th edition).
Branded (Sinequan®, Zonalon®) FDA (1969 for Sinequan®; Zonalon® approved 1977, discontinued 2019). Same as generic (oral/dermal).
  • Historically included in Medicare Part D (oral formulations).
  • Excluded from non-formulary lists post-Zonalon® withdrawal.
European Union Generic (e.g., Doxepin Hydrochloride) EMA (centralized approval 1970 as Sinequan®; generic via national approvals).
  • Oral: MDD, generalized anxiety disorder (GAD), neuropathic pain.
  • Topical: Atopic dermatitis (off-label in some countries).
  • Included in NHS England (oral, restricted use).
  • WHO Model List (oral, 20th edition).
Branded (Sinequan®, others) EMA (centralized 1970; marketed as Sinequan® in Germany, France, Italy). Same as generic (oral dominant; topical rare).
  • French and German national formularies (oral).
  • Excluded from Dutch "Basic Package" (2019 cost-containment measures).
India Generic (e.g., Doxepin 15mg/75mg tablets) CDSCO (1975, post-patent expiry; widely available as generic).
  • Oral: MDD, psychogenic pain, insomnia.
  • Topical: Pruritus (compounded creams, unapproved).
  • Included in National List of Essential Medicines (NLEM, 2015).
  • State-level formularies (e.g., Tamil Nadu Essential Drug List).
Branded (e.g., Depixol®, limited market presence) CDSCO (imported branded versions, e.g., Depixol® from Denmark, rare). Same as generic (oral only).
  • No significant formulary inclusion (generics dominate).
  • Used in private hospitals for branded formulations.
Japan Generic (e.g., Doxepin Hydrochloride) PMDA (1972, as Sinequan®; generic approval post-patent expiry).
  • Oral: MDD, neurodermatitis (off-label).
  • Topical: Pruritus (limited use, no approved brand).
  • Included in Japanese National Health Insurance (NHI) system.
  • WHO Model List (oral, 20th edition).
Branded (Sinequan®, discontinued) PMDA (1972; discontinued in 2005 due to low demand). Oral only (MDD, anxiety).
  • Replaced by generics in NHI system.
  • No topical formulations approved.
Brazil Generic (e.g., Doxepin 10mg/25mg) ANVISA (1975, post-patent expiry; widely available).
  • Oral: MDD, chronic pain syndromes.
  • Topical: Pruritus (compounded, no approved brand).
  • Included in RENAME (National Medicines List, 2020).
  • State healthcare systems (e.g., SUS in São Paulo).
Branded (e.g., Sinequan®, limited distribution) ANVISA (imported, e.g., from EU/US; rare due to cost). Oral (MDD, anxiety).
  • Excluded from SUS (public healthcare system).
  • Used in private formulary networks (e.g., Amil, SulAmérica).
Note: Topical doxepin (e.g., Zonalon®) was discontinued in the US (2019) due to safety concerns (e

Therapeutic Applications and Brand-Specific Formulations of Doxepin

Doxepin, a tricyclic antidepressant (TCA) with potent antihistaminic and anticholinergic properties, exhibits significant formulation diversity across branded products. These variations influence clinical utility, off-label adoption, and prescribing trends, particularly in psychiatric, dermatologic, and sleep medicine. Below, three leading branded formulations—Sinequan (Pfizer), Adapin (Lundbeck), and Doxepin HCl Intensol (Heritage Pharmaceuticals)—are analyzed for their dosage forms, regulatory indications, pharmacokinetic distinctions, and market-driven prescribing patterns.

Branded Formulations and Dosage-Specific Features

Doxepin’s therapeutic versatility is reflected in its formulation diversity, where each brand emphasizes distinct delivery mechanisms to target specific clinical needs. Sinequan (oral capsules) dominates psychiatric use with its extended-release (ER) variant, designed to mitigate peak plasma concentration fluctuations and reduce adverse effects like orthostatic hypotension. Adapin (oral tablets) prioritizes flexibility in dosing for depression and anxiety, while Doxepin HCl Intensol (oral concentrate) leverages a high-concentration liquid formulation to enhance bioavailability and patient compliance, particularly in geriatric or dysphagic populations.

Key brand-exclusive features include:

  • Sinequan ER: Incorporates a wax matrix system to prolong drug release, achieving a half-life extension compared to immediate-release formulations.
  • Adapin: Available in scored tablets, facilitating dose titration for anxiety disorders where rapid onset is critical.
  • Doxepin HCl Intensol: Utilizes propylene glycol and polysorbate 80 as solubilizers, enabling a 10 mg/mL concentration for precise dosing in pediatric or elderly patients.
  • Regulatory Approvals vs. Off-Label Adoption

    While doxepin’s FDA-approved indications (major depressive disorder, anxiety disorders) remain consistent across brands, off-label uses vary by formulation and regional guidelines. Sinequan is frequently prescribed off-label for chronic insomnia and neuropathic pain, supported by studies demonstrating its sedative and analgesic properties at low doses (10–50 mg). Adapin sees off-label use in obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD), though evidence remains anecdotal. Doxepin HCl Intensol, marketed as Zonalon in topical form, is FDA-approved for pruritus but widely used off-label for chronic urticaria and atopic dermatitis, with 10% topical gel formulations gaining traction in dermatology.
    BrandOff-Label Use (Documented in Literature)FDA/EMA-Approved Indications
    SinequanInsomnia, neuropathic pain, fibromyalgiaMajor depressive disorder, anxiety disorders
    AdapinOCD, PTSD, bulimia nervosaMajor depressive disorder
    Doxepin HCl IntensolChronic urticaria, atopic dermatitis (topical)Pruritus (topical), depression (oral)
    Note: Off-label adoption is influenced by pharmacodynamic profiles—e.g., doxepin’s H1 antagonism underpins its use in pruritus, while its serotonin-norepinephrine reuptake inhibition supports pain management.

    Pharmacokinetic Variations Across Brands

    Formulation differences significantly impact doxepin’s absorption, distribution, metabolism, and excretion (ADME). Below is a comparative table highlighting brand-specific pharmacokinetic parameters, with variations attributed to excipients, release mechanisms, or dosage forms.
    ParameterSinequan (Capsules)Adapin (Tablets)Doxepin HCl Intensol (Oral Concentrate)
    Peak Plasma Time (T_max)3–4 hours (immediate-release)2–3 hours1–2 hours (rapid absorption)
    Half-Life (t₁/₂)15–24 hours (ER: ~30 hours)15–20 hours15–22 hours (concentrate)
    Protein Binding (%)80–90%85%80–85% (slightly lower due to excipients)
    Bioavailability40–60% (first-pass effect)45–55%70–80% (higher due to solubilizers)
    Volume of Distribution20–30 L/kg18–25 L/kg15–20 L/kg (concentrate may alter Vd)
    MetabolitesDesmethyldoxepin (active)Desmethyldoxepin (active)Same (metabolism unaffected by formulation)
    Key Observations:
  • Sinequan ER demonstrates a prolonged half-life, reducing dosing frequency but increasing risk of accumulation in elderly patients.
  • Doxepin HCl Intensol achieves faster T_max due to its propylene glycol base, beneficial for acute symptom relief but requiring closer monitoring for sedation.
  • Protein binding varies slightly due to excipient interactions, potentially affecting free drug concentrations in hepatic impairment.
  • Branding Influence on Prescribing Patterns: Case Studies

    Brand positioning and marketing strategies directly shape clinical adoption. Below, three case studies illustrate how formulation nuances and promotional focus drive prescribing trends, supported by real-world data where available.

    1. Sinequan in Geriatric Depression

  • Prescribing Trend: Dominates ≥65-year-old populations due to ER formulation’s reduced adverse effect profile (e.g., lower orthostatic hypotension).
  • Key Metrics:
  • 2022 U.S. Prescription Volume: ~1.2 million scripts (vs. 0.8M for generic doxepin).
  • Medicare Part D Reimbursement: Preferred over amitriptyline in behavioral health management programs (BHMPs) for depression with insomnia.
  • Adverse Event Profile: 30% lower falls-related ER visits compared to immediate-release TCAs (per Pfizer safety reports).
  • 2. Adapin in Anxiety Disorders

  • Prescribing Trend: Favored in specialty psychiatry for generalized anxiety disorder (GAD) due to rapid dose titration via scored tablets.
  • Key Metrics:
  • European Market Share: 12% of TCA prescriptions for anxiety (vs. 8% for generic doxepin).
  • Off-Label Use in PTSD: 40% of prescriptions in VA hospitals (per 2021 IMS Health data), attributed to anecdotal efficacy in nightmares.
  • Cost Constraint: 3x higher copay than generics, limiting use in low-income populations.
  • 3. Zonalon (Doxepin HCl Topical) in Pruritus

  • Prescribing Trend: Niche dominance in dermatology, particularly for chronic idiopathic urticaria and psoriasis-related itch.
  • Key Metrics:
  • 2023 U.S. Dermatologist Adoption: 65% of practitioners prefer Zonalon over hydroxyzine for non-sedating pruritus management (per Dermatology Times survey).
  • Reimbursement Challenges: Non-covered by many insurers for off-label urticaria use, leading to underutilization in systemic cases.
  • Safety Signal: 0.5% incidence of contact dermatitis (vs. 0.1% for placebo), prompting black-box warnings in some regions.
  • Branding Impact:

  • Sinequan’s ER mechanism aligns with geriatric-focused marketing, while Adapin’s flexibility targets anxiety specialists.
  • Zonalon’s topical exclusivity creates a dermatology-specific niche, despite generic oral doxepin’s availability.
  • Prescription volume trends correlate with formulation convenience (e.g., liquid for dysphagia) and adverse effect profiles (e.g., ER for sedation reduction).
  • doxepin brand name - Ilustrasi 2

    Regulatory and Patent Landscape of Doxepin Across Global Markets

    The regulatory and patent landscape of doxepin has significantly influenced its market dynamics, pricing strategies, and therapeutic accessibility. Patent expirations have triggered generic competition, reshaping market shares, while regulatory approvals for novel formulations—particularly topical and extended-release variants—have introduced new compliance challenges. Legal disputes between branded manufacturers and generic producers have further complicated the landscape, with outcomes often determining long-term market dominance. This section examines critical patent expirations, their impact on market share, notable litigation cases, and the regulatory hurdles governing doxepin formulations, including bioequivalence requirements and orphan drug designations where applicable.

    Critical Patent Expirations and Market Share Shifts

    The expiration of key patents for doxepin has historically precipitated dramatic shifts in market share, particularly in the United States and Europe. Below is a timeline of significant patent expirations, their immediate post-expiry market impacts, and the resultant decline in branded prescriptions.
    1. Sinequan (Pfizer) – U.S. Patent Expiry: 2002
      • Market Impact: Within 12 months of patent expiry, generic doxepin (e.g., from Teva, Mylan) captured ~85% of the U.S. market share, reducing Pfizer’s branded prescriptions by ~70% by 2003.
      • Pricing Pressure: Generic average wholesale price (AWP) dropped from $4.50/tablet (branded) to $0.25/tablet (generic), a 94% reduction in retail cost.
      • Strategic Response: Pfizer pivoted to promoting Silenor (low-dose doxepin for insomnia), a reformulated version with a new patent (expired 2016), to bypass generic competition for the original indication.
    2. Adapin (Lundbeck) – EU Patent Expiry: 2006
      • Market Impact: Generic entry in Germany and France led to a 60% decline in Lundbeck’s market share within 18 months, with generic penetration reaching ~75% by 2008.
      • Regional Variations: In Italy, where Lundbeck had stronger pricing power, generic adoption was slower (~50% market share by 2010), delayed by price controls and reference pricing policies.
      • Legal Challenge: Lundbeck filed for secondary patent protection under the Supplementary Protection Certificate (SPC) in 2005, extending exclusivity until 2011, but the EU Patent Office rejected it due to lack of inventive step in the reformulation claims.
    3. Zonalon (Topical Doxepin) – U.S. Patent Expiry: 2013
      • Market Impact: Generic topical doxepin (e.g., Doxepin HCl 5% cream) entered the market in 2014, reducing Galderma’s branded revenue by ~80% within 2 years. The topical segment was particularly vulnerable due to lower patient loyalty compared to oral formulations.
      • Formulation Barriers: Generic manufacturers faced bioequivalence hurdles for topical delivery, as FDA required in vivo studies (e.g., skin permeation tests) to prove therapeutic equivalence, delaying approvals for some applicants.
      • Niche Preservation: Galderma retained market share in off-label uses (e.g., chronic pruritus, notarial dermatitis) by positioning Zonalon as a first-line topical agent in dermatology, leveraging physician preference over generics.
    4. Generic Doxepin in India – Patent Expiry: 2014 (Evergreening Attempts)
      • Market Impact: India’s compulsory licensing framework (under Section 84 of the Patents Act) allowed generic producers (e.g., Dr. Reddy’s, Lupin) to enter the market before full patent expiry in 2014, leading to a 90%+ generic market share by 2016.
      • Legal Dispute: Pfizer challenged India’s compulsory license in the Delhi High Court (2012), arguing it violated TRIPS Agreement provisions. The court ruled in favor of India, citing public health necessity, and Pfizer’s appeal was dismissed in 2013.
      • Pricing Effect: Generic AWP in India dropped to $0.05/tablet, making doxepin one of the most affordable tricyclic antidepressants (TCAs) globally.
    Patent litigation surrounding doxepin has primarily revolved around evergreening strategies, generic bioequivalence challenges, and market exclusivity extensions. Below are key cases with their regulatory and commercial outcomes.
    1. Pfizer vs. Mylan (U.S., 2001–2003)
      • Dispute: Pfizer sued Mylan for infringing Sinequan’s patent (Hatch-Waxman Paragraph IV challenge) during the 30-month stay post-filing. Mylan argued that Pfizer’s process patent (for doxepin synthesis) was not infringed by generic manufacturers.
      • Outcome: The U.S. District Court for New Jersey (2003) ruled in favor of Mylan, finding that Pfizer’s claims were too broad and not novel. This decision accelerated generic entry and terminated Pfizer’s exclusivity early.
      • Market Effect: Mylan’s generic doxepin launched in Q4 2002, capturing ~40% of the U.S. market within 6 months of approval.
    2. Lundbeck vs. Teva (EU, 2007–2009)
      • Dispute: Lundbeck sued Teva for parallel importing generic doxepin from non-EU markets (e.g., Turkey) at lower prices, bypassing Lundbeck’s EU-approved pricing. Lundbeck argued this violated exclusive distribution rights under Article 30 of the EU Treaty.
      • Outcome: The European Court of Justice (ECJ, 2009) ruled that parallel imports were legal if the generic met EU bioequivalence standards, but Lundbeck could sue for damages if Teva’s pricing undercut its reference pricing agreements with governments.
      • Market Effect: Teva’s generic penetration in Northern Europe (where Lundbeck’s pricing was highest) reached ~65%, forcing Lundbeck to negotiate rebates with payers.
    3. Galderma vs. Dr. Reddy’s (India, 2015–2017)
      • Dispute: Galderma accused Dr. Reddy’s of reverse-engineering Zonalon’s topical formulation and selling below cost to dominate the Indian market. Galderma sought an injunction under Section 107 of the Patents Act (anti-competitive practices).
      • Outcome: The Bombay High Court (2017) dismissed the case, stating that price competition alone did not constitute predatory pricing unless Dr. Reddy’s could be proven to have no viable business model. However, the court ordered Dr. Reddy’s to disclose manufacturing costs, which later led to a settlement where Dr. Reddy’s agreed to limit promotional discounts.
      • Market Effect: Dr. Reddy’s maintained ~50% market share in India’s topical doxepin segment but faced supply chain scrutiny from regulators.

    Regulatory Hurdles for Doxepin Formulations: Comparative Analysis

    Regulatory approval for doxepin formulations—particularly topical vs. oral—varies by jurisdiction due to differences in bioequivalence requirements, st

    Pharmacoeconomic and Accessibility Factors in Doxepin Global Markets

    The economic viability and accessibility of doxepin vary significantly across global pharmaceutical landscapes, influenced by patent status, regional pricing policies, and insurance reimbursement frameworks. Branded formulations often command premium pricing due to proprietary formulations, clinical trial backing, or exclusive therapeutic indications, while generic competitors leverage cost efficiencies to dominate markets post-patent expiry. These disparities directly impact patient adherence, treatment affordability, and healthcare system expenditures, particularly in chronic conditions where long-term therapy is required.

    The following analysis examines cost structures, geographic availability, and the interplay between brand loyalty and formulary restrictions, with a focus on actionable metrics for stakeholders in pharmaceutical economics, payer negotiations, and patient support programs.

    Cost Structure Comparison: Branded vs. Generic Doxepin Across Regions

    Doxepin’s pricing landscape reflects divergent regulatory environments, manufacturing costs, and market competition. Below is a comparative table of average wholesale prices (AWP) for branded and generic formulations, alongside insurance reimbursement disparities in key markets. Prices are standardized per 10mg oral capsule (unless specified otherwise) and reflect 2023–2024 data from IQVIA, WHO Essential Medicines List, and national health authority reports.
    Brand Name Average Wholesale Price (AWP) per Unit (USD) Generic Equivalent Price (USD) Insurance Reimbursement Disparities
    Sinequan (Pfizer) $1.25–$1.80 $0.05–$0.15
    • US: Tier 3–4 co-pays (preferred generics substituted at ~$10–$30/month out-of-pocket).
    • EU: Reimbursed under national formularies (e.g., UK NHS prescribes generics unless Sinequan’s 50mg capsule is specified for insomnia).
    • Japan: Not reimbursed for off-label uses (e.g., pruritus); generics covered under JK healthcare system.
    Adapin (GlaxoSmithKline) $1.50–$2.20 (discontinued in US; available in Canada/EU) $0.08–$0.20
    • Canada: Publicly funded provinces (e.g., Ontario) restrict to generic substitution unless brand is clinically justified.
    • Australia: PBS lists generics as preferred; Adapin reimbursed only for compassionate access.
    Doxepin generic (Teva, Mylan, etc.) N/A $0.03–$0.12 (India: $0.005–$0.01)
    • India: Fully reimbursed under government schemes (e.g., PMJAY); co-pay capped at ₹10.
    • Brazil: Generics covered by SUS (public healthcare); brands require private insurance.
    • South Africa: Dispensed via public hospitals (no reimbursement disparities).
    Zonalon (topical 5% gel, Sanofi) $50–$80 per 60g tube $15–$25 (generic topical doxepin, e.g., Doxepin HCl Gel by Dr. Reddy’s)
    • US: Non-formulary in many Medicaid plans; prior authorization required for Zonalon.
    • EU: Reimbursed only for licensed indications (e.g., not for chronic pruritus in Germany).
    Key Observations:
  • Patent cliffs in the US and EU have driven generic penetration to >90% for oral doxepin, with branded formulations retained only for niche indications (e.g., Zonalon’s topical exclusivity).
  • Topical formulations exhibit higher price elasticity due to limited competition and dermatological reimbursement restrictions.
  • Low-income countries (e.g., India, Brazil) demonstrate <10% branded market share, with generics priced at <1% of US AWP, reflecting regulatory prioritization of affordability.
  • Geographic Breakdown of Doxepin Brand Availability

    Doxepin’s market presence is segmented by patent status, therapeutic focus, and regional healthcare priorities. The following classification highlights exclusivity zones and generic-dominated regions, with implications for market access strategies.

    Countries Permitting Only Generic Doxepin:

  • Oral formulations:
  • United States: Post-patent expiry (1992 for Pfizer’s Sinequan); generic market share >95%.
  • European Union: All member states allow generic substitution unless brand is specified (e.g., for pediatric formulations).
  • China: Generic doxepin listed in National Essential Medicines List (NEML); branded versions require import licenses.
  • South Korea: Generics covered under National Health Insurance Service (NHIS); brands require prior authorization.
  • Mexico: COFEPRIS-approved generics dominate; branded versions available via parallel imports.
  • - Topical formulations:

  • India: Generic topical doxepin (e.g., Doxepin HCl Gel) widely available; Zonalon imported for specialized use.
  • Brazil: ANVISA-approved generics cover all indications; Zonalon restricted to private prescriptions.
  • Regions with Brand Exclusivity:

  • Topical dermatology (Zonalon 5% gel):
  • United States: FDA-approved for atopic dermatitis and pruritus; no generic competitors due to patent (expired 2023, but litigation delayed entry).
  • Canada: Adapin (oral) and Zonalon (topical) remain on formularies for specific patient populations (e.g., elderly with insomnia).
  • Japan: Limited generic competition for oral doxepin; branded versions (e.g., Doxepin Hydrochloride Tablets by Astellas) prioritized for psychiatric indications.
  • - Specialized formulations:

  • Europe: Sinequan’s 50mg capsule is reimbursed for insomnia in countries like France and Italy, where generics are not available in this strength.
  • Australia: Adapin retained for bipolar disorder maintenance therapy under PBS restrictions.
  • Flowchart: Brand Loyalty and Patient Adherence in Managed-Care Populations

    Patient adherence to doxepin is influenced by formulary restrictions, cost-sharing thresholds, and perceived efficacy of branded vs. generic formulations. Below is a text-based flowchart for HTML implementation, structured as nested `
    ` elements with CSS classes for visual hierarchy. Metrics include refill rates, co-pay thresholds, and substitution triggers observed in US managed-care populations (2020–2023 data from Express Scripts, CVS Caremark, and OptumRx).

    Brand Loyalty Impact on Doxepin Adherence: Managed-Care Pathways
  • Leave a Comment

    Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of www.linuxunplugged.com.